Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Merck's challenge to medicare drug pricing could cause ‘narrative shift' in pharma, says Jared Holz
06:59pm, Tuesday, 06'th Jun 2023
Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to discuss Merck's lawsuit against the federal government over Medicare drug pricing.
Merck sues U.S. government over Medicare drug pricing negotiation
05:29pm, Tuesday, 06'th Jun 2023
Merck is suing the U.S. government over a law that lets Medicare negotiate drug prices. Yahoo Finance health care reporter Anjalee Khemlani explains why Merck is upset over the law.
Markets Rise Modestly as Semiconductor and Regional Bank Stocks Gain
04:55pm, Tuesday, 06'th Jun 2023
Markets rose modestly on Tuesday, June 6, 2023, as semiconductor and regional bank stocks gained.
Dow Jones Today: Index Higher on Bank Bounce
04:55pm, Tuesday, 06'th Jun 2023
The Dow Jones Industrial Average finished the session essentially flat, with tech and financial stocks helping give the index a 0.03% boost.
Merck Sues To Stop Medicare Drug Negotiation
01:00pm, Tuesday, 06'th Jun 2023
Merck (MRK), the New Jersey-based maker of widely-used cancer treatment Keytruda, filed a lawsuit Tuesday in a federal court in Washington seeking to block the drug negotiation program, created by the
Merck just sued the Biden administration: find out why
11:12am, Tuesday, 06'th Jun 2023
Merck & Co Inc (NYSE: MRK) is in focus this morning after the pharmaceutical giant sued the Biden administration in a federal district court. Here's what inspired the lawsuit In its complaint, the mul
Merck sues U.S. government over Medicare drug price negotiations
10:07am, Tuesday, 06'th Jun 2023
CNBC's Bertha Coombs joins 'Squawk on the Street' with the latest news from Merck.
Merck sues federal government over Medicare drug price negotiation
09:49am, Tuesday, 06'th Jun 2023
Merck & Co. MRK, +0.42% on Tuesday filed a lawsuit against the federal government over the Medicare drug price negotiation program established last year as part of the Inflation Reduction Act. The pro
Merck Sues US Over Inflation Reduction Act
09:25am, Tuesday, 06'th Jun 2023
The suit names as defendants the U.S. Department of Health & Human Services, its secretary Xavier Becerra, the Center for Medicare & Medicaid Services, and its administrator, Chiquita Brooks-LaSure.
Merck sues Biden administration over Medicare drug price negotiations
08:58am, Tuesday, 06'th Jun 2023
In a scathing complaint filed in federal district court, Merck excoriated the Medicare price negotiation process as a "sham" and "tantamount to extortion."
Merck sues US government to halt Medicare drug price negotiation
08:52am, Tuesday, 06'th Jun 2023
Merck & Co said it sued the U.S. government on Tuesday, seeking an injunction of the drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth a
Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
06:45am, Tuesday, 06'th Jun 2023
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference.
Merck & Co., Inc. (MRK) Presents at Special Event (Oncology Investor Event at ASCO 2023) Transcript
02:53am, Tuesday, 06'th Jun 2023
Merck & Co., Inc. (NYSE:MRK ) Special Event (Oncology Investor Event at ASCO 2023) June 5, 2023 7:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dean Li - President, Merck Research Laboratori
Merck Is Climbing Higher, With Growth Potential
10:48pm, Monday, 05'th Jun 2023
Merck & Co is a strong investment option due to its steady growth in the pharmaceutical industry and potential for minimal risk. The company's key products, Januvia for diabetes and Keytruda for cance
Moderna and Merck reveal new data on individualized cancer treatment
09:19am, Monday, 05'th Jun 2023
Moderna MRNA, +1.55% and Merck & Co. MRK, +1.43% on Monday released new results from a trial evaluating Moderna's mRNA-based investigational individualized neoantigen therapy in combination with Merck
